XENE
Income statement / Annual
Last year (2025), Xenon Pharmaceuticals Inc's total revenue was $7.50 M,
and the percentage change from the previous year is not available.
In 2025, Xenon Pharmaceuticals Inc's net income was -$345.91 M.
See Xenon Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$7.50 M |
$0.00 |
$0.00 |
$9.43 M |
$18.44 M |
$32.17 M |
$6.83 M |
$0.00 |
$311.00 K |
$1.80 M |
| Cost of Revenue |
$2.54 M
|
$2.56 M
|
$167.51 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.00 M
|
$25.57 M
|
$1.11 M
|
| Gross Profit |
$4.96 M
|
-$2.56 M
|
-$167.51 M
|
$9.43 M
|
$18.44 M
|
$32.17 M
|
$6.83 M
|
-$6.00 M
|
-$25.26 M
|
$689.00 K
|
| Gross Profit Ratio |
0.66
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
-81.23
|
0.38
|
| Research and Development Expenses |
$300.94 M
|
$210.39 M
|
$167.51 M
|
$105.77 M
|
$75.46 M
|
$50.52 M
|
$38.85 M
|
$23.63 M
|
$25.57 M
|
$19.83 M
|
| General & Administrative Expenses |
$79.63 M
|
$68.90 M
|
$46.54 M
|
$32.81 M
|
$21.97 M
|
$12.94 M
|
$10.80 M
|
$8.38 M
|
$7.31 M
|
$6.79 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$79.63 M
|
$68.90 M
|
$46.54 M
|
$32.81 M
|
$21.97 M
|
$12.94 M
|
$10.80 M
|
$8.38 M
|
$7.31 M
|
$6.79 M
|
| Other Expenses |
-$2.54 M
|
-$2.56 M
|
-$167.51 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$378.03 M
|
$276.74 M
|
$46.54 M
|
$138.58 M
|
$97.43 M
|
$63.47 M
|
$49.65 M
|
$32.02 M
|
$32.89 M
|
$26.62 M
|
| Cost And Expenses |
$380.57 M
|
$279.30 M
|
$214.05 M
|
$138.58 M
|
$97.43 M
|
$63.47 M
|
$49.65 M
|
$38.02 M
|
$32.89 M
|
$26.62 M
|
| Interest Income |
$26.83 M
|
$41.94 M
|
$27.62 M
|
$8.71 M
|
$466.00 K
|
$2.28 M
|
$2.35 M
|
$1.22 M
|
$477.00 K
|
$504.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$484.00 K
|
$1.43 M
|
$1.39 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.54 M
|
$2.56 M
|
$3.54 M
|
$1.41 M
|
$906.00 K
|
$644.00 K
|
$429.00 K
|
$586.00 K
|
$649.00 K
|
$864.00 K
|
| EBITDA |
-$342.35 M |
-$235.86 M |
-$210.51 M |
-$127.74 M |
-$78.09 M |
-$27.97 M |
-$39.76 M |
-$32.54 M |
-$30.06 M |
-$23.95 M |
| EBITDA Ratio |
-45.65
|
0
|
0
|
-13.54
|
-4.24
|
-0.87
|
-5.82
|
0
|
-96.64
|
-13.29
|
| Operating Income Ratio |
-49.74
|
0
|
0
|
-13.69
|
-4.28
|
-0.97
|
-6.27
|
0
|
-104.74
|
-13.76
|
| Total Other Income/Expenses Net |
$28.18 M
|
$40.88 M
|
$31.37 M
|
$3.89 M
|
$105.00 K
|
$2.21 M
|
$1.20 M
|
$6.40 M
|
$1.87 M
|
$1.82 M
|
| Income Before Tax |
-$344.89 M
|
-$238.42 M
|
-$182.69 M
|
-$125.26 M
|
-$78.89 M
|
-$29.09 M
|
-$41.62 M
|
-$34.50 M
|
-$30.70 M
|
-$23.00 M
|
| Income Before Tax Ratio |
-45.99
|
0
|
0
|
-13.28
|
-4.28
|
-0.9
|
-6.09
|
0
|
-98.73
|
-12.75
|
| Income Tax Expense |
$1.02 M
|
-$4.09 M
|
-$292.00 K
|
$118.00 K
|
-$6.00 K
|
-$257.00 K
|
-$23.00 K
|
$4.91 M
|
$0.00
|
$0.00
|
| Net Income |
-$345.91 M
|
-$234.33 M
|
-$182.39 M
|
-$125.37 M
|
-$78.88 M
|
-$28.84 M
|
-$41.60 M
|
-$34.50 M
|
-$30.70 M
|
-$23.00 M
|
| Net Income Ratio |
-46.12
|
0
|
0
|
-13.29
|
-4.28
|
-0.9
|
-6.09
|
0
|
-98.73
|
-12.75
|
| EPS |
-4.36 |
-3.01 |
-2.73 |
-2.06 |
-1.77 |
-0.83 |
-1.54 |
-1.78 |
-1.71 |
-1.48 |
| EPS Diluted |
-4.36 |
-3.01 |
-2.73 |
-2.06 |
-1.77 |
-0.83 |
-1.54 |
-1.78 |
-1.71 |
-1.48 |
| Weighted Average Shares Out |
$79.25 M
|
$77.89 M
|
$66.89 M
|
$60.54 M
|
$43.63 M
|
$34.54 M
|
$25.94 M
|
$19.43 M
|
$17.99 M
|
$15.49 M
|
| Weighted Average Shares Out Diluted |
$79.25 M
|
$77.89 M
|
$66.89 M
|
$60.54 M
|
$43.63 M
|
$34.54 M
|
$25.94 M
|
$19.43 M
|
$18.00 M
|
$15.49 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
